Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. Here, we report yet another novel pathway in which sorafenib can induce apoptotic cell death preferentially and efficaciously on an experimentally proven drug- and radio-resistant human Hep G2 cells via a mitochondria-dependent oxidative stress mechanism. A real time confocal imaging assay revealed that sorafenib could rapidly provoke the production of ROS plethorically, mainly concentrating in the mitochondria, albeit substantial amounts of ROS could also be detected in cytosol and nucleus. The rapid production of ROS could simultaneously induce intracellular glutathione (iGSH) depletion. A nearly 90% of iGSH was found to be depleted in 1h period after the cells received the drug treatment. Besides mitochondria, iGSH depletion could also be detected in other cellular compartment including cytoplasm and nucleus. Interestingly, we also demonstrated that sorafenib could trigger mitochondrial Ca(2+) overload. All these events compoundedly serve as the final arbitrator to initiate lethal apoptotic process through the release of cytochrome c and caspase 3/7 activation. Collectively, we provide first evidence here that sorafenib can provoke an alternative pathway for apoptosis induction of Hep G2 cells through a mitochondria-dependent oxidative stress mechanism which is independent of original kinase inhibitory attribute of the drug action. Most importantly, we also demonstrate that sorafenib can effectively eradicate a highly drug- and radio-resistant HCC cells. Thus, our data can provide the basis for a potential applicability of sorafenib in a combined treatment modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Söderdahl, T., Enoksson, M., Lundberg, M., Holmgren, A., Ottersen, O. P., Orrenius, S., Bolcsfoldi, G., & Cotgreave, I. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0259fje · Cited by 99
Cited by
Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J., Mazière, J., Chauffert, B., & Galmiche, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28159 · Cited by 602
Role of metabolism in cancer cell radioresistance and radiosensitization methods
Tang, L., Wei, F., Wu, Y., He, Y., Shi, L., Xiong, F., Gong, Z., Guo, C., Li, X., Deng, H., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0758-7 · Cited by 409
Reactive Oxygen Species‐Mediated Mechanisms of Action of Targeted Cancer Therapy
Teppo, H.-R., Soini, Y., & Karihtala, P. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1485283 · Cited by 162
Wang, R., Xia, L., Gabrilove, J., Waxman, S., & Jing, Y. (2013) · Leukemia · doi:10.1038/leu.2012.180 · Cited by 85
“In addition, sorafenib has been found to decrease GSH levels in hepatocellular carcinoma cells (47).”
Background
Metadata
- Authors
- Chiou, J.-F., Tai, C.-J., Wang, Y.-H., Liu, T.-Z., Jen, Y.-M., & Shiau, C.-Y.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2009-10-15
- Volume
- 8
- Issue
- 20
- Pages
- 1904-1913
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2001679154
- Cited by
- 75
- References
- 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.